Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Concentrix First Quarter 2026 Earnings Call - AI bookings surge while margins remain pressured
Concentrix delivered a steady top line and clear evidence that its AI push is moving from promise to commercial traction, but the transition is compressing near-term margins. Revenue was roughly $2.5 ...
- Revenue was approximately $2.5 billion in Q1 2026, up 1.9% on a constant currency basis and over 5% on a reported basis.
- Signed annual contract value for solutions including AI more than doubled quarter over quarter, signaling a sharp shift in go-to-market mix toward higher-value tech offerings.
- Wins with technology were up more than 61% year over year in Q1, and Concentrix closed close to 60 enterprise iX suite deals in the quarter, including its largest iX Hero contracts to date with two Fortune 50 clients.
- +15 more takeaways
Sanara MedTech Q4 2025 Earnings Call - Surpassed $100M Revenue, Reaffirmed 2026 Guidance Backed by Vizient Win
Sanara MedTech closed 2025 with clear momentum, crossing $100.0 million of net revenue for the first time, expanding gross margins to about 93%, and producing positive operating cash flow despite the ...
- Sanara MedTech generated $103.1 million of net revenue in full year 2025, up 19% year over year, the first time the company exceeded $100 million.
- Fourth quarter 2025 net revenue was $27.5 million, up 5% year over year, or up 13% ex the $1.8 million of Hurricane Helene driven BIASURGE sales in Q4 2024.
- Gross margin expanded roughly 200 basis points to approximately 93% for full year 2025, with Q4 gross margin ~93%, driven by soft tissue product mix and lower CellerateRX Surgical manufacturing costs.
- +12 more takeaways
NRx Pharmaceuticals Q4 2025 Earnings Call - KETAFREE bioequivalence clears path to commercialization; one hit could drive profitability
NRx reported concrete progress across three near-term commercial and regulatory paths, with a preliminary FDA determination of bioequivalence for its preservative-free ketamine candidate, KETAFREE, po...
- FDA issued a preliminary determination of bioequivalence for KETAFREE versus Ketalar, a major hurdle cleared for the ANDA pathway.
- NRx manufactured three registration batches of KETAFREE, with plans for about 200,000 blow-fill-seal units to be warehoused at approval.
- Company filed a suitability petition in August 2025 and an ANDA in September 2025; FDA stability review and pre-approval plant inspection remain as standard final steps.
- +12 more takeaways
Cheetah Mobile Q4 2025 Earnings Call - Non-GAAP Profitability Achieved as AI and Robotics Take Half the Revenue
Cheetah Mobile says 2025 was a reset year, with internet cash flow stabilizing the business while AI and robotics moved from lab curiosity to meaningful revenue. Management touts full year non-GAAP op...
- Management says 2025 marked a stabilization, with total revenue up materially year over year, management citing growth in the mid-to-high 40% range and total revenue of roughly RMB 1,150 million for the year.
- Company reported full year non-GAAP operating profit of RMB 14 million, its first non-GAAP operating profitability in six years, while GAAP operating loss narrowed to RMB 179 million from RMB 437 million in 2024.
- AI and other businesses became a dominant mix shift, accounting for roughly half of total revenue in the fourth quarter and about 46.5% for the full year, per management statements.
- +13 more takeaways
LightInTheBox Q4 2025 Earnings Call - Record Q4 Profit as Branded Apparel and AI Drive Margin Expansion
LightInTheBox reported a clear turnaround in 2025, posting consecutive profitable quarters and a record Q4 net income as the company shifts from a pure e-commerce model to a consumer lifestyle and bra...
- Q4 2025 revenue: $63.0 million, up 9% year-over-year, marking renewed top-line growth in the quarter.
- Q4 2025 gross profit: $39.0 million, up 16% year-over-year; Q4 gross margin rose to 63% from 59% a year earlier.
- Q4 2025 net income: $3.3 million, versus $0.5 million in Q4 2024, the company’s highest quarterly profit since 2022.
- +12 more takeaways
Avino Silver & Gold Mines Q4 and Year-end 2025 Earnings Call - Record $92M Revenues, $102M Cash, La Preciosa Moves Into Extraction
Avino closed 2025 with a clean, heavy-hitting quarter. The company reported record annual revenue of $92.2 million, a cash balance of $102 million and roughly $99 million in working capital, while Q4 ...
- Record full-year revenue of $92.2 million for 2025, and record Q4 revenue of over $30 million.
- Cash on hand reached $102 million at year-end, with working capital of about $99 million.
- Q4 marked a return to primary silver, with silver accounting for 54% of consolidated revenues in the quarter.
- +17 more takeaways
The Beauty Health Company Q4 2025 Earnings Call - Margins Stabilize; 2026 Execution Year, Growth Targeted for 2027
New CEO Pedro Malha, five months on the job, laid out a clear pivot. BeautyHealth is moving from a device placement story to a utilization and consumables-first play, leaning on a 36,000+ installed ba...
- New CEO Pedro Malha (five months tenure) is repositioning the company from device placements to device utilization, emphasizing activation of the 36,000+ installed base.
- Q4 2025 revenue was $82.4 million, down 1.3% year-over-year, a notable improvement versus prior double-digit declines earlier in the year.
- Consumables, the recurring revenue engine, grew 1.7% year-over-year to $57.7 million, highlighting resilience in treatment demand.
- +12 more takeaways
Talphera Q4 2025 Earnings Call - Niyad (nafamostat) Poised to Replace Heparin and Simplify CRRT Anticoagulation
Talphera used its analyst event to push the case that Niyad, its formulation of nafamostat, could materially change anticoagulation in continuous renal replacement therapy. The company announced it ha...
- Talphera reported the NEPHRO CRRT study has reached 50% enrollment, which triggered a $4.1 million tranche; earlier closings added proceeds and as of Dec 31 cash and investments were $20.4 million.
- Management expects to complete enrollment later this year and to file a PMA roughly three months after study completion, targeting a second half 2026 submission. The primary endpoint is a 24-hour circuit outcome, allowing a quick data turnaround.
- Investigators say current CRRT anticoagulation practice is inconsistent: many centers use no anticoagulation, some use heparin, others use citrate, and protocols vary widely across hospitals.
- +9 more takeaways
Caledonia Mining Corporation FY2025 Earnings Call - Gold Rally Funds Bilboes Push, $150m Convertible Secured
Caledonia closed 2025 on a strong, price-driven note, with revenue up 46% to $267 million and EBITDA doubling to $125.3 million. Management says the windfall from higher gold prices, paired with disci...
- Revenue rose 46% to $267 million in FY2025, gross profit was $137 million, EBITDA rose 109% to $125.3 million, and profit after tax was $67.5 million.
- Blanket Mine produced 76,000 ounces in 2025, Bilboes oxide produced 1,683 ounces, total group production ~79,000 ounces; sales 77,000 oz from Blanket.
- The financial outperformance was largely driven by a higher gold price; management repeatedly acknowledged results were price-led rather than purely operational.
- +13 more takeaways
BioLineRx Q4 2025 and Full Year 2025 Earnings Call - GLIX1 IND Approved; First-in-Human GBM Trial Launch Imminent
BioLineRx pivoted decisively in 2025, with GLIX1 emerging as the new lead asset. The Hemispherian IND was cleared, orphan designations were secured in the U.S. and EU, and a first-in-human phase I/II-...
- GLIX1 IND approved and cleared for first-in-human trials, with company on track to initiate the phase I/II-A GBM study by the end of the month.
- GLIX1 received orphan drug designation from both the FDA and the European Medicines Agency, which can accelerate review and provide market exclusivity incentives.
- Phase I portion will enroll up to 30 recurrent or progressive GBM and high-grade glioma patients, primary objective is safety and determination of maximum tolerated or recommended dose; data from phase I expected in the first half of next year according to management.
- +14 more takeaways